Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 3
1980 3
1981 1
1982 5
1983 1
1984 1
1986 1
1987 1
1988 1
1989 2
1990 2
1992 1
1997 2
1999 2
2001 1
2003 1
2004 1
2005 1
2006 1
2009 1
2012 2
2013 2
2014 2
2015 1
2016 1
2017 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
Elhabazi K, Humbert JP, Bertin I, Quillet R, Utard V, Schneider S, Schmitt M, Bourguignon JJ, Laboureyras E, Ben Boujema M, Simonnet G, Ancel C, Simonneaux V, Beltramo M, Bucher B, Sorg T, Meziane H, Schneider E, Petit-Demoulière B, Ilien B, Bihel F, Simonin F. Elhabazi K, et al. Among authors: ilien b. Neuropharmacology. 2017 May 15;118:188-198. doi: 10.1016/j.neuropharm.2017.03.012. Epub 2017 Mar 10. Neuropharmacology. 2017. PMID: 28288815
Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
Elhabazi K, Humbert JP, Bertin I, Schmitt M, Bihel F, Bourguignon JJ, Bucher B, Becker JA, Sorg T, Meziane H, Petit-Demoulière B, Ilien B, Simonin F. Elhabazi K, et al. Among authors: ilien b. Neuropharmacology. 2013 Dec;75:164-71. doi: 10.1016/j.neuropharm.2013.07.012. Epub 2013 Aug 2. Neuropharmacology. 2013. PMID: 23911743
41 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page